Skip to main content
KalVista Pharmaceuticals, Inc logo
Menu toggle

Main navigation

  • About KalVista
    • Senior Management
    • Board of Directors
    • Contact Us
    • Careers
  • Products & Pipeline
    • Pipeline
    • KalVista for HAE
    • KVD900
    • KVD824
    • Factor XIIa
    • KalVista for DME
    • Publications
  • For Patients
    • HAE Resources
    • KVD900
    • KVD824
    • Factor XIIa
    • DME Resources
  • For Healthcare Providers
    • HAE Resources
    • KVD900
    • KVD824
    • Factor XIIa
    • DME Resources
    • Publications
    • Expanded Access
  • For Investors
    • Stock Information
    • News Releases
    • Events Calendar
    • Presentations
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance

KalVista Pharmaceuticals
creating a new generation of small molecule protease inhibitors for HAE and DME

Hereditary Angioedema (HAE)

Diabetic Macular Edema (DME)

News

Kalvista Pharmaceuticals

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

Nov 9, 2020
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

Oct 15, 2020
Kalvista Pharmaceuticals

KalVista Pharmaceuticals Reports First Fiscal Quarter Results

Sep 14, 2020
All News
  • Print Page
  • Email Alerts
  • RSS
  • Search

Footer

  • About KalVista
  • Products & Pipeline
  • For Patients
  • For Healthcare Providers
  • For Investors
  • Contact Us
+1 (857) 999 0075 info@kalvista.com

Social Menu

  • Linked In
  • Twitter
Copyright © 2021 | All rights reserved.

Footer Bottom

  • KalVista Terms
  • Privacy